Invokana / Farxiga / Jardiance / Invokamet / Xigduo / Glyxambi / Synjardy / Qtern / Steglatro / Steglujan / Segluromet
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
The diabetes Type-2 drugs Invokana, Farxiga, and Jardiance, as well as Invokamet, Xigduo, Glyxambi, Synjardy, Qtern, Steglatro, Steglujan, and Segluromet have been associated with these serious side effects:
- Fournier’s Gangrene (Necrotizing Fasciitis of the Perineum)
- Leg Amputations
- Foot Amputations
- Toe(s) Amputations
All of these diabetes drugs are Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors, a new class of diabetes medicines.
We are currently investigating possible drug injury lawsuits against the responsible pharmaceutical companies for diabetes patients who have developed the medical conditions listed above.
We encourage you to submit a Drug Injury Law Case Review – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible drug injury case. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, nor some other lawyer — about your case based on his many years of experience.
Most Recent Article About These Drugs
The FDA has identified 55 unique cases of Fournier gangrene associated with diabetes drugs in the Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors class between March 1, 2013 and January 31, 2019. Of those Fournier gangrene cases, 21 cases were associated with Invokana (canagliflozin), 18 cases were associated with Jardiance (empagliflozin), and 16 cases were associated with Farxiga (dapagliflozin).
To read more of this article, click below:
This information comes from a new FDA analysis article, “Fournier Gangrene Associated With Sodium–Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases”, published in May 2019 by the medical journal Annals of Internal Medicine.
Lead author Susan Bersoff-Matcha, MD, of the FDA’s Center for Drug Evaluation and Research, and her colleagues emphasized that doctors should carefully watch patients on SGLT2 inhibitors for signs of Fournier gangrene. Further, they made this important point in their article: “Serious complications and death are likely if [Fournier gangrene (FG)] is not recognized immediately and surgical intervention is not carried out within the first few hours of diagnosis.”
In August 2018 the FDA added a warning about the increased risk of developing Fournier gangrene, also known as necrotizing fasciitis of the perineum, to the drug labels for all SGLT2 inhibitors, based on 12 cases reported from March 2013 to May 2018. Now, with this May 2019 medical journal article, there is more evidence that a class of diabetes drugs which includes Invokana, Jardiance, and Farxiga can cause a serious infection in the genital area known as Fournier gangrene.[View article in full at original source]
Earlier articles by attorney Tom Lamb on the Side Effects Blog:
- Lower Limb Amputations From All SGLT2 Inhibitors, or Just Invokana?
- Farxiga And Jardiance Have Two-Time Increased Risk For Amputations
- Amputations Are Diabetes Drugs Side Effects For SGLT2 Inhibitors Class
- Lower Limbs Amputations Are SGLT-2 Inhibitors Drug-Class Side Effects
- Fournier’s Gangrene: Side Effect For Invokana, Farxiga, And Jardiance
- Increased Risks Of Lower-Limb Amputations For Farxiga And Jardiance
- Invokana, Jardiance, And Farxiga Have Increased Risks Of Amputations
- Jardiance – Lower Limb Amputations Drug Safety Issue Remains Uncertain
- New Analysis Finds An Increased Risk Of Bladder Cancer For Jardiance
- Invokana – Amputations: No Explanation Yet As Regards “How” And “Why”
- “Dear Doctor” Letter About Invokana And Amputations Was Sent In Canada
- FDA Reports Show Extent And Nature of Invokana-Amputation Side Effect
- Invokana Gets “Black-Box Warning” For Risk Of Leg And Foot Amputations
- Jardiance, Invokana, And Farxiga Double Risk Of Diabetic Ketoacidosis
- Farxiga MDL Includes Diabetic Ketoacidosis And Kidney Damage Lawsuits
- Federal Court Invokana MDL In New Jersey With Judge Brian Martinotti
- New Federal Court Multidistrict Litigation (MDL) For Farxiga Lawsuits
- Invokana Has New Warning About Risk Of Lower Limb Amputation In Canada
List of SGLT2 Inhibitors
|Drug Name||Active Ingredient(s)||Drug Manufacturer||FDA Approval Date|
|Invokamet||canagliflozin / metformin||Janssen Pharmaceuticals||2014|
|Invokamet XR||canagliflozin / metformin extended-release||Janssen Pharmaceuticals||2016|
|Xigduo XR||dapagliflozin / metformin extended-release||AstraZeneca Pharmaceuticals||2014|
|Qtern||dapagliflozin / saxagliptin||AstraZeneca Pharmaceuticals||2017|
|Jardiance||empagliflozin||Boehringer Ingelheim Pharmaceuticals||2014|
|Glyxambi||empagliflozin / linagliptin||Boehringer Ingelheim Pharmaceuticals||2015|
|Synjardy||empagliflozin / metformin hydrochloride||Boehringer Ingelheim Pharmaceuticals / Eli Lilly and Company||2015|
|Synjardy XR||empagliflozin / metformin hydrochloride extended-release||Boehringer Ingelheim Pharmaceuticals / Eli Lilly and Company||2016|
|Steglatro||ertugliflozin||Merck Sharp & Dohme Corp. / Pfizer Inc.||2017|
|Steglujan||ertugliflozin / sitagliptin||Merck Sharp & Dohme Corp. / Pfizer Inc.||2017|
|Segluromet||ertugliflozin / metformin hydrochloride||Merck Sharp & Dohme Corp. / Pfizer Inc.||2017|
All content by attorney Tom Lamb